SCHRODINGER INC (SDGR)
Health Care · NASDAQ
Physics-based computational platform that accelerates drug discovery and materials science by predicting molecular properties with high accuracy, enabling faster, cheaper, and more successful drug development.
What SCHRODINGER INC does
Schrödinger operates a physics-based computational platform that enables faster, more cost-effective discovery of novel molecules for drug development and materials applications compared to traditional methods. The company generates revenue through two segments: software licensing to biopharmaceutical companies, industrial firms, academic institutions, and government laboratories; and drug discovery programs conducted both collaboratively with major pharma partners and through proprietary pipeline advancement. The software solutions accelerate all stages of molecular discovery, design, and optimization by predicting critical molecular properties with high accuracy, thereby reducing development timelines and failure rates.
Themes: ["Computational drug discovery / molecular property prediction","AI-driven small molecule design","Biopharmaceutical software platforms","Materials science / advanced materials discovery","Clinical-stage drug development / therapeutics"]
Fundamentals
- Price$16.79 as of 2026-07-09 close
- Market cap$1.2B as of 2026-07-10
- 1-year return-22.6% as of 2026-07-09 close
- Net margin-40.6% as of 2026-07-10
- Gross margin+55.3% as of 2026-07-10
- ROE-30.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+10.6% as of 2026-07-10
- Revenue CAGR (3y)+12.2% SEC XBRL
- Beta1.64 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Exscientia
- Atomwise
- BenevolentAI
- Benchling
- Valo Health
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.